Citadel Advisors’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-15,400
| Closed | -$263K | – | 15153 |
|
|
2021
Q2 | $263K | Sell |
15,400
-2,600
| -14% | -$48.7K | ﹤0.01% | 11596 |
|
|
2021
Q1 | $376K | Sell |
18,000
-13,300
| -42% | -$307K | ﹤0.01% | 10334 |
|
|
2020
Q4 | $717K | Buy |
31,300
+8,900
| +40% | +$169K | ﹤0.01% | 7460 |
|
|
2020
Q3 | $365K | Buy |
22,400
+11,900
| +113% | +$216K | ﹤0.01% | 7810 |
|
|
2020
Q2 | $142K | Buy |
+10,500
| New | +$122K | ﹤0.01% | 8785 |
|
|
2020
Q1 | – | Sell |
-15,500
| Closed | -$386K | – | 10443 |
|
|
2019
Q4 | $386K | Buy |
15,500
+4,400
| +40% | +$89.2K | ﹤0.01% | 7210 |
|
|
2019
Q3 | $189K | Sell |
11,100
-5,600
| -34% | -$102K | ﹤0.01% | 8188 |
|
|
2019
Q2 | $380K | Buy |
16,700
+100
| +0.6% | +$2.7K | ﹤0.01% | 7234 |
|
|
2019
Q1 | $534K | Sell |
16,600
-64,600
| -80% | -$2M | ﹤0.01% | 6679 |
|
|
2018
Q4 | $2.29M | Sell |
81,200
-20,400
| -20% | -$597K | ﹤0.01% | 3934 |
|
|
2018
Q3 | $2.92M | Buy |
101,600
+61,600
| +154% | +$1.85M | ﹤0.01% | 3776 |
|
|
2018
Q2 | $1.5M | Buy |
40,000
+31,600
| +376% | +$1.24M | ﹤0.01% | 4543 |
|
|
2018
Q1 | $330K | Sell |
8,400
-3,200
| -28% | -$117K | ﹤0.01% | 6593 |
|
|
2017
Q4 | $376K | Buy |
11,600
+3,800
| +49% | +$114K | ﹤0.01% | 6102 |
|
|
2017
Q3 | $243K | Buy |
+7,800
| New | +$231K | ﹤0.01% | 6388 |
|
Citadel Advisors's XENT Position: Q2 2022 in Review
Citadel Advisors sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 140,474 shares — an estimated $3.94M sold.
Citadel Advisors first reported a position in XENT in Q3 2014 and held it in 27 quarters. The position peaked at $22.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Citadel Advisors reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Citadel Advisors sold 140,474 Intersect ENT, Inc shares in Q2 2022, an estimated $3.94M.
- Citadel Advisors first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 27 quarters.
- Citadel Advisors's Intersect ENT, Inc position peaked at $22.6M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.